Renmin Hospital of Wuhan University
武汉大学人民医院
Listed for 17 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Renmin Hospital of Wuhan University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌13 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌12 papers led2 open trials led
- Hepatocellular carcinoma肝细胞癌84 papers led
- Stomach cancer胃癌73 papers led1 open trial led
- Retinoblastoma视网膜母细胞瘤4 papers led
- Osteosarcoma骨肉瘤30 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
- Neuroblastoma神经母细胞瘤10 papers led
- Myasthenia gravis重症肌无力0 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
- Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症3 papers led
- Behçet disease白塞病2 papers led
- Alport syndromeAlport 综合征0 papers led
- IgA nephropathyIgA 肾病2 papers led
- Familial adenomatous polyposis家族性腺瘤性息肉病2 papers led
- Leber hereditary optic neuropathyLeber 遗传性视神经病变2 papers led
Not listed for: Hepatoblastoma, Chordoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 13 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
6 hospitals in Wuhan for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingQL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06749899
Age 18 years to 65 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan
- RecruitingImmune Score Based Radiomics in Nasopharyngeal Carcinoma
- Phase
- Not given
- Started
- 2021-11
- Registry
- NCT05126160
Age 18 years to 70 years (registered criteria)
Led by Zhejiang Cancer Hospital; 4 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou, Wuhan
- RecruitingA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- Phase
- Phase 1
- Started
- 2021-11
- Registry
- NCT05194982
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chongqing, Guangzhou, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led13
- Homing Effect Directed Cuprous Delivery Activates Cuproptosis Against Nasopharyngeal Carcinoma and Metastasis.
- Molecular network analysis of CPEB4 translational control and targeting CPEB4/β-catenin to modulate invasion and migration of nasopharyngeal carcinoma cells.
- CENPN suppresses autophagy and increases paclitaxel resistance in nasopharyngeal carcinoma cells by inhibiting the CREB-VAMP8 signaling axis.
- Predicting prognosis of nasopharyngeal carcinoma based on deep learning: peritumoral region should be valued.
- Deep Learning for Predicting Distant Metastasis in Patients with Nasopharyngeal Carcinoma Based on Pre-Radiotherapy Magnetic Resonance Imaging.
- MiR-3612 targeting THBS1 suppresses nasopharyngeal carcinoma progression by PI3K/AKT signaling pathway.
- Enhancing nasopharyngeal carcinoma cell radiosensitivity by suppressing AKT/mTOR via CENP-N knockdown.
- Regorafenib inhibits growth, survival and angiogenesis in nasopharyngeal carcinoma and is synergistic with Mcl-1 inhibitor.
- (S,R)3-(4-Hydroxyphenyl)-4,5-Dihydro-5-Isoxazole Acetic Acid Methyl Ester Inhibits Epithelial-to-Mesenchymal Transition Through TGF-β/Smad4 Axis in Nasopharyngeal Carcinoma.
- Deep learning for locally advanced nasopharyngeal carcinoma prognostication based on pre- and post-treatment MRI.
- LncRNA FAM225A activates the cGAS-STING signaling pathway by combining FUS to promote CENP-N expression and regulates the progression of nasopharyngeal carcinoma.
- Overexpression of Notch2 enhances radiosensitivity via inhibition of the AKT/mTOR signaling pathway in nasopharyngeal carcinoma.
- Ginkgolic Acid Suppresses Nasopharyngeal Carcinoma Growth by Inducing Apoptosis and Inhibiting AKT/NF-κB Signaling.
All its trials on ClinicalTrials.gov, any status4
- QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
- Immune Score Based Radiomics in Nasopharyngeal Carcinoma
- Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
More papers found outside PubMed (not counted)16
- 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm
- Evaluation of Trident network against atlas and 2D U-net methods for auto-segmentation of organs at risk in nasopharyngeal carcinoma: a comparative study
- Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma
- Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Boosting Advanced Nasopharyngeal Carcinoma Stage Prediction Using a Two-Stage Classification Framework Based on Deep Learning
- Correction to: Boosting Advanced Nasopharyngeal Carcinoma Stage Prediction Using a Two‑Stage Classification Framework Based on Deep Learning
- Long Non-coding RNA PANDAR Promotes Radioresistance in Nasopharyngeal Carcinoma via SIRT1/Ku70/PI3K/Akt Pathway
- S100A14 Induces Apoptosis and Negatively Regulates Proliferation of Nasopharyngeal Carcinoma Cells
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 12 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.
- Open trials as a site
- 0
- led by another institution
5 hospitals in Wuhan for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingInfluence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
- Phase
- Not given
- Started
- 2023-05
- Registry
- NCT05894369
Age 18 years to 80 years (registered criteria)
Led by Renmin Hospital of Wuhan UniversityWuhan
- RecruitingA Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2023-07
- Registry
- NCT05919030
Age 18 years to Not stated (registered criteria)
Led by Renmin Hospital of Wuhan UniversityWuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led12
- Elaiophylin targets EIF4B to suppress the growth of esophageal squamous cell carcinoma via the PI3K/AKT signaling pathway.
- Porphyromonas gingivalis extracellular vesicles promotes tumor metastasis in esophageal squamous cell carcinoma by inducing PRKACB/JNK/ NFATC2 axis.
- Immune Cellular Patterns Predicting Lymph Node Status Helps Personalized Management of Stage T1 Esophageal Squamous Cell Carcinoma.
- Efficacy and Safety of Second-Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.
- A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
- Human-Like Artificial Intelligent System for Predicting Invasion Depth of Esophageal Squamous Cell Carcinoma Using Magnifying Narrow-Band Imaging Endoscopy: A Retrospective Multicenter Study.
- Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression and chemoresistance by enhancing the secretion of chemotherapy-induced senescence-associated secretory phenotype via activation of DNA damage response pathway.
- Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
- Fusobacterium nucleatum promotes proliferation in oesophageal squamous cell carcinoma via AHR/CYP1A1 signalling.
- KISS-1, Mediated by Promoter Methylation, Suppresses Esophageal Squamous Cell Carcinoma Metastasis via MMP2/9/MAPK Axis.
- Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma.
- Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: A propensity score matching and landmark analyses.
All its trials on ClinicalTrials.gov, any status3
- A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
- Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)13
- The Transcription Factor ELK1 Promotes Esophageal Squamous Cell Carcinoma Progression by Activating the CDK4/Wnt/β-catenin Pathway
- Novel Roles of HOXD11 and HOXD13 in Mediating Response to Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
- Prediction of lymph node status in stage T1 esophageal squamous cell carcinoma.
- A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
- A prospective clinical trial of camrelizumab in combination with chemoradiotherapy in patients with metastatic esophageal squamous cell carcinoma.
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
- Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma
- Prognosis and Benefit Factors of Definitive Concurrent Chemoradiotherapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma
- Relationship between ENO1 and Metastasis Risk and Prognosis in Esophageal squamous cell carcinoma
- Clinical Parameters Predicting Prognosis for Elderly Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma
- Elaiophylin Targets EIF4B to Regulate the Proliferation, Invasion, and Apoptosis of Esophageal Squamous Cancer Cells via the PI3K/AKT Signaling Pathway
- Elaiophylin Targets EIF4B to Regulate the Proliferation, Invasion, and Apoptosis of Esophageal Squamous Cell Carcinoma via the PI3K/AKT Signaling Pathway
- Elaiophylin Targets EIF4B to Regulate the Proliferation, Invasion, and Apoptosis of Esophageal Squamous Cell Carcinoma via the PI3K/AKT Signaling Pathway
Cancer
Hepatocellular carcinoma
肝细胞癌Led 84 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Wuhan for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led84
- Structurally diverse tetrahydroxanthone analogues from Paraconiothyrium sp. AC31 with pyroptosis induction through targeted inhibition of PARP1 in hepatocellular carcinoma cells.
- CYP8B1 inhibits hepatocellular carcinoma progression by repressing PAK4 transcription through inhibition of nuclear translocation of u-STAT1.
- Splenic volume as a predictor of survival in cancer patients treated with immune checkpoint inhibitors.
- Comprehensive analysis of mitochondrial solute carrier family 25 (SLC25) identifies member 19 (SLC25A19) as a regulatory factor in hepatocellular carcinoma.
- The prognostic significance and potential mechanism of PFDN4 in hepatocellular carcinoma.
- NSMCE2 promotes the occurrence and development of HCC by regulating the SUMOylation of PPARα.
- Multi-Omics Integration: Predicting Progression and Optimizing Clinical Treatment of Hepatocellular Carcinoma Through Malignant-Cell-Related Genes.
- Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients.
- Metal-organic framework nanoparticles activate cGAS-STING pathway to improve radiotherapy sensitivity.
- m6A-modified circCCAR1 promotes malignant proliferation by enhancing KIF5B expression in hepatocellular carcinoma.
- m6A regulators-based gene expression pattern is associated with immune microenvironment characteristics in hepatocellular carcinoma.
- Single-cell landscape of dynamic changes in CD8+ T cells, CD4+ T cells and exhausted T cells in hepatocellular carcinoma.
- Nanodelivery of Y-27632 by RGD-modified liposome enhances radioimmunotherapy of hepatocellular carcinoma via tumor microenvironment matrix stiffness reprogramming.
- The Role of HBx Mutations in Chronic Hepatitis B with Acute Exacerbation.
- Prognostic impact of body composition in hepatocellular carcinoma patients with immunotherapy.
- C-X-C motif chemokine receptor 4 inhibition promotes the effect of plantamajoside in hepatocellular carcinoma.
- Matrix stiffness-related extracellular matrix signatures and the DYNLL1 protein promote hepatocellular carcinoma progression through the Wnt/β-catenin pathway.
- Knockdown of SLC16A3 decreases extracellular lactate concentration in hepatocellular carcinoma, alleviates hypoxia and induces ferroptosis.
- USP30 promotes the progression of breast cancer by stabilising Snail.
- Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy.
- A Novel Cholesterol Metabolism-Related lncRNA Signature Predicts the Prognosis of Patients with Hepatocellular Carcinoma and Their Response to Immunotherapy.
- IGFALS suppresses hepatocellular carcinoma progression by stabilizing PPAR-γ.
- Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases.
- S100A16 is a potential target for reshaping the tumor microenvironment in the hypoxic context of liver cancer.
- Association between ascites Gustave Roussy immune score and the intratumoural microbiome in malignant ascites secondary to hepatocellular carcinoma.
- Deciphering the molecular interplay and tumorigenesis in hepatocellular carcinoma through insights into FBXL6 and KRASG12D.
- Transcription factor RELA promotes hepatocellular carcinoma progression by promoting the transcription of m6A modulator METTL3.
- Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
- High tumor burden score indicated the unfavorable prognosis in patients with hepatocellular carcinoma: A meta-analysis.
- Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma.
- The prognostic significance and potential mechanism of DBF4 zinc finger in hepatocellular carcinoma.
- Ascitic microbiota alteration is associated with portal vein tumor thrombosis occurrence and prognosis in hepatocellular carcinoma.
- Apoprotein E methylation is correlated with immune microenvironment in hepatocellular carcinoma.
- Prognostic value and immunological role of CSNK1D in human cancers.
- A comprehensive survival and prognosis analysis of GPR55 expression in hepatocellular carcinoma.
- Construction of a T-cell exhaustion-related gene signature for predicting prognosis and immune response in hepatocellular carcinoma.
- ATP6V1F is a novel prognostic biomarker and potential immunotherapy target for hepatocellular carcinoma.
- Basement membrane-related regulators for prediction of prognoses and responses to diverse therapies in hepatocellular carcinoma.
- Comprehensive analysis of scRNA-Seq and bulk RNA-Seq data reveals dynamic changes in tumor-associated neutrophils in the tumor microenvironment of hepatocellular carcinoma and leads to the establishment of a neutrophil-related prognostic mo
- An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma.
- GNB1 promotes hepatocellular carcinoma progression by targeting BAG2 to activate P38/MAPK signaling.
- USP25 promotes hepatocellular carcinoma progression by interacting with TRIM21 via the Wnt/β-catenin signaling pathway.
- FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis.
- Targeting WDxR motif reprograms immune microenvironment and inhibits hepatocellular carcinoma progression.
- Nomogram model for predicting esophsagogastric varices in hepatocellular carcinoma with cirrhosis.
- Construction and validation of a nomogram for patients with multiple hepatocellular carcinoma: A SEER-based study.
- KIFC3 regulates progression of hepatocellular carcinoma via EMT and the AKT/mTOR pathway.
- Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
- High intramuscular adipose tissue content associated with prognosis and postoperative complications of cancers.
- Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on NK cell marker genes to predict prognosis and immunotherapy response in hepatocellular carcinoma.
- The application of nanoparticles in immunotherapy for hepatocellular carcinoma.
- Recent updates on targeting the molecular mediators of NAFLD.
- Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma.
- Evaluation of Serum FGL1 as Diagnostic Markers for HBV-Related Hepatocellular Carcinoma.
- Two fragments of HBV DNA integrated into chrX: 11009033 and its genetic regulation in HepG2.2.15.
- Construction and validation of 3-genes hypoxia-related prognostic signature to predict the prognosis and therapeutic response of hepatocellular carcinoma patients.
- Characteristics of lactate metabolism phenotype in hepatocellular carcinoma.
- Genes Modulating Butyrate Metabolism for Assessing Clinical Prognosis and Responses to Systematic Therapies in Hepatocellular Carcinoma.
- PSMD12 promotes the activation of the MEK-ERK pathway by upregulating KIF15 to promote the malignant progression of liver cancer.
- Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody.
- USF2-mediated upregulation of TXNRD1 contributes to hepatocellular carcinoma progression by activating Akt/mTOR signaling.
- Differential expression of insulin-like growth factor type 1 receptor identifies heterogeneous intrahepatic regulatory T subsets in mouse hepatocellular carcinoma.
- RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma.
- A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients.
- Low-grade hepatocellular carcinoma characteristics, a practical nomogram and risk stratification system: a SEER population-based study.
- The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors.
- Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma.
- Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma.
- Letter to the Editor: Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival.
- Declining disease burden of HCC in the United States, 1992-2017: A population-based analysis.
- CircRNA_0040705 promotes the progression of hepatocellular carcinoma.
- Protein succinylation associated with the progress of hepatocellular carcinoma.
- Research Progress in Alpha-fetoprotein-induced Immunosuppression of Liver Cancer.
- ROS-Related miRNAs Regulate Immune Response and Chemoradiotherapy Sensitivity in Hepatocellular Carcinoma by Comprehensive Analysis and Experiment.
- ADAM15 correlates with prognosis, immune infiltration and apoptosis in hepatocellular carcinoma.
- Identification of a Nine Immune-Related lncRNA Signature as a Novel Diagnostic Biomarker for Hepatocellular Carcinoma.
- Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients
- Long non-coding RNA LINC00630 facilitates hepatocellular carcinoma progression through recruiting transcription factor E2F1 to up-regulate cyclin-dependent kinase 2 expression.
- Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.
- Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma.
- Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma.
- Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome.
- System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma.
- Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status2
Cancer
Stomach cancer
胃癌Led 73 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.8%.
5 hospitals in Wuhan for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSamples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
- Phase
- Not given
- Started
- 2020-12
- Registry
- NCT03972956
Age 18 years to 80 years (registered criteria)
Led by Renmin Hospital of Wuhan UniversityWuhan
- RecruitingMultimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
- Phase
- Not given
- Started
- 2026-02
- Registry
- NCT07401199
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShijiazhuang, Wuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led73
- Artificial intelligence assistance narrows the experience gap in endoscopic reporting of gastric lesions: a prospective clinical trial.
- Efficacy of endoscopic therapy in patients with T1b gastric cancer and construction of a prognostic prediction model: a retrospective cohort study and multicenter validation study.
- Amylin inhibits gastric cancer progression by targeting CCN1 and affecting the PI3K/AKT signalling pathway.
- Global status and attributable risk factors of esophageal, stomach, colorectal cancers in adolescents and young adults: global burden of disease 2021 study analysis.
- Clinical implications of DNA ploidy, stroma, and nucleotyping in predicting peritoneal metastasis risk for gastric cancer.
- Development and verification of a radiomics model to forecast Ki67 index and prognosis in advanced gastric tubular adenocarcinoma.
- Screening and surveillance of hereditary upper GI cancers.
- LncRNA FIRRE drives gastric cancer progression via ZFP64-mediated TUBB3 promoter activation.
- Comprehensive proteomic analysis and multidimensional model construction of peritoneal metastasis in gastric cancer.
- SIRT1 Expression in Human Gastrointestinal Tumors and Its Clinical Significance.
- Clinical decision tree for optimizing endoscopic assessment of signet ring cell carcinoma in hereditary diffuse gastric cancer surveillance.
- The mechanism of Weiqi decoction treating gastric cancer: a work based on network pharmacology and experimental verification.
- Trends in Stomach Cancer Burden in China: A Joinpoint and APC Analysis Based on GBD 2021.
- Integrated Genomic Analysis Identifies Clinically Relevant Molecular Subtypes and Disulfidptosis-Related Prognostic Signature of Gastric Cancer.
- A prognostic model for gastric cancer constructed by multiple machine learning algorithms.
- First-Line Apatinib Combined with Tislelizumab and Chemotherapy for Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma with Poor Prognosis.
- Advancements in non-invasive diagnosis of gastric cancer.
- Integrated multi-omics analysis and machine learning identify hub genes and potential mechanisms of resistance to immunotherapy in gastric cancer.
- System-wide identification of novel de-ubiquitination targets for USP10 in gastric cancer metastasis through multi-omics screening.
- TRIM47 drives gastric cancer cell proliferation and invasion by regulating CYLD protein stability.
- Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers.
- An artificial intelligence system for chronic atrophic gastritis diagnosis and risk stratification under white light endoscopy.
- Co-Expression Network Analysis and Molecular Docking Demonstrate That Diosgenin Inhibits Gastric Cancer Progression via SLC1A5/mTORC1 Pathway.
- Macrophages enhance cisplatin resistance in gastric cancer through the transfer of circTEX2.
- Gastric neoplasm detection of computer-aided detection-assisted esophagogastroduodenoscopy changes with implement scenarios: a real-world study.
- The effect of incorporating domain knowledge with deep learning in identifying benign and malignant gastric whitish lesions: A retrospective study.
- Pterostilbene suppresses gastric cancer proliferation and metastasis by inhibiting oncogenic JAK2/STAT3 signaling: In vitro and in vivo therapeutic intervention.
- Role of ATP citrate lyase and its complementary partner on fatty acid synthesis in gastric cancer.
- Double-nylon purse-string suture in closing postoperative wounds following endoscopic resection of large (≥ 3 cm) gastric submucosal tumors.
- Identification of GNG7 as a novel biomarker and potential therapeutic target for gastric cancer via bioinformatic analysis and in vitro experiments.
- Baicalin enhances the efficacy of 5-Fluorouracil in gastric cancer by promoting ROS-mediated ferroptosis.
- Age-specific cardiovascular disease-related mortality among patients with major gastrointestinal cancers: A SEER population-based study.
- Special AT-rich sequence binding protein 1 promotes multidrug resistance in gastric cancer by regulation of Ezrin to alter subcellular localization of ATP-binding cassette transporters.
- Identifying the key genes of Epstein-Barr virus-regulated tumour immune microenvironment of gastric carcinomas.
- KIFC3 Regulates the progression and metastasis of gastric cancer via Notch1 pathway.
- A deep-learning based system using multi-modal data for diagnosing gastric neoplasms in real-time (with video).
- CircSOD2 polarizes macrophages towards the M1 phenotype to alleviate cisplatin resistance in gastric cancer cells by targeting the miR-1296/STAT1 axis.
- The Use of Antibiotics During Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Advanced Esophagogastric Cancer.
- Exploring the challenge of early gastric cancer diagnostic AI system face in multiple centers and its potential solutions.
- Thymoquinone induces apoptosis and protective autophagy in gastric cancer cells by inhibiting the PI3K/Akt/mTOR pathway.
- Targeted labeling with tissue marking dyes guided by magnifying endoscopy of endoscopic submucosal dissection specimen improves the accuracy of endoscopic and histopathological diagnosis of early gastric cancer: a before-after study.
- The effectiveness of a computer-aided system in improving the detection rate of gastric neoplasm and early gastric cancer: study protocol for a multi-centre, randomized controlled trial.
- Comparison of Helicobacter pylori positive and negative gastric cancer via multi-omics analysis.
- Key Molecules of Fatty Acid Metabolism in Gastric Cancer.
- Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody.
- miR-137 Modulates Human Gastric Cancer Cell Proliferation, Apoptosis, and Migration by Targeting EZH2.
- Real-time use of artificial intelligence for diagnosing early gastric cancer by magnifying image-enhanced endoscopy: a multicenter diagnostic study (with videos).
- Real-time artificial intelligence for detecting focal lesions and diagnosing neoplasms of the stomach by white-light endoscopy (with videos).
- Deep learning system compared with expert endoscopists in predicting early gastric cancer and its invasion depth and differentiation status (with videos).
- The Application of Two-Stage Operation for High-Risk Patients with Oesophageal Cancer Following Gastrectomy.
- Identifying novel therapeutic targets in gastric cancer using genome-wide CRISPR-Cas9 screening.
- Paeonol inhibits the malignancy of Apatinib-resistant gastric cancer cells via LINC00665/miR-665/MAPK1 axis.
- Cell differentiation trajectory predicts patient potential immunotherapy response and prognosis in gastric cancer.
- Long non-coding RNA LINC00511 regulates the expression of microRNA-625-5p and activates signal transducers and activators of transcription 3 (STAT3) to accelerate the progression of gastric cancer.
- MicroRNA-1269b inhibits gastric cancer development through regulating methyltransferase-like 3 (METTL3).
- Silencing of long non-coding RNA HCP5 inhibits proliferation, invasion, migration, and promotes apoptosis via regulation of miR-299-3p/SMAD5 axis in gastric cancer cells.
- Identification of a novel immune prognostic model in gastric cancer.
- Radiotherapy benefited the survival of patients with intestinal-type gastric adenocarcinoma: a SEER population-based study.
- Reconstruction of the esophagus of patients with middle thoracic esophageal carcinoma using the remnant stomach following Billroth II gastrectomy.
- Accurate diagnosis and prognosis prediction of gastric cancer using deep learning on digital pathological images: A retrospective multicentre study.
- Evaluation of the effects of an artificial intelligence system on endoscopy quality and preliminary testing of its performance in detecting early gastric cancer: a randomized controlled trial.
- A deep learning-based system for identifying differentiation status and delineating the margins of early gastric cancer in magnifying narrow-band imaging endoscopy.
- MicroRNA-328-3p facilitates the progression of gastric cancer via KEAP1/NRF2 axis.
- Propionibacterium acnes overabundance in gastric cancer promote M2 polarization of macrophages via a TLR4/PI3K/Akt signaling.
- Artificial intelligence in the diagnosis of gastric precancerous conditions by image-enhanced endoscopy: a multicenter, diagnostic study (with video).
- Pyroptosis Patterns Characterized by Distinct Tumor Microenvironment Infiltration Landscapes in Gastric Cancer.
- Having gastroesophageal cancer is associated with increased risk of severe COVID-19-related events in patients with digestive tract cancer: A multicenter, retrospective, cohort study.
- Artificial intelligence in upper GI endoscopy - current status, challenges and future promise.
- Proximal gastrectomy with double-tract reconstruction versus total gastrectomy for proximal early gastric cancer: A systematic review and meta-analysis.
- Identification of hub genes and construction of an mRNA-miRNA-lncRNA network of gastric carcinoma using integrated bioinformatics analysis.
- Identification of stem cell-related subtypes and risk scoring for gastric cancer based on stem genomic profiling.
- The Clinicopathological Features and Overall Survival of Patients With Gastric Neuroendocrine Carcinoma.
- Effect of a deep learning-based system on the miss rate of gastric neoplasms during upper gastrointestinal endoscopy: a single-centre, tandem, randomised controlled trial.
Chinese-language papers (not in the count)3
All its trials on ClinicalTrials.gov, any status5
- Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
- First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC
- Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
- Development of a Multimodal AI System for GIST Management
- Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis
Cancer
Retinoblastoma
视网膜母细胞瘤Led 4 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 1.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
18 hospitals in Wuhan for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Comprehensive analysis of single-cell and bulk RNA sequencing uncover tumor microenvironment diversity in invasive Retinoblastoma.
- GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells.
- The anticancer effects of 7-Methoxyheptaphylline against the human retinoblastoma cells are facilitated via S-phase cell cycle arrest, mitochondrial apoptosis and inhibition of Wnt/β-catenin signalling pathway.
- The Results of Pars Plana Vitrectomy in the Treatment of Intraocular Retinoblastoma: A Retrospective Study and Literature Review.
Earlier papers (2016–2020)4
- Inhibition of anticancer growth in Retinoblastoma cells by naturally occurring sesquiterpene nootkatone is mediated via autophagy, endogenous ROS production, cell cycle arrest and inhibition of NF-κB signalling pathway.
- The anticancer effects of 7-Methoxyheptaphylline against the human retinoblastoma cells are facilitated via S-phase cell cycle arrest, mitochondrial apoptosis and inhibition of Wnt/β-catenin signalling pathway.
- Bioinformatics analysis of multi-omics data identifying molecular biomarker candidates and epigenetically regulatory targets associated with retinoblastoma.
- Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling.
All its trials on ClinicalTrials.gov, any status1
Cancer
Osteosarcoma
骨肉瘤Led 30 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
31 hospitals in Wuhan for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led30
- TRIM17 promotes the progression of osteosarcoma by regulating PDK1 m6A modification-mediated AKT/mTOR pathway activation through ubiquitination of FTO.
- ABLIM1 promotes the proliferation, migration and invasion of osteosarcoma through DCC mediated activation of PI3K/AKT signaling pathway.
- IRF2BPL inhibits proliferation, migration and invasion of osteosarcoma cells by inhibiting FOSL2-mediated PI3K/AKT pathway activation.
- Bayesian Optimization-Enhanced Machine Learning for Osteosarcoma Risk Stratification Based on Sphingolipid Metabolism.
- RNF207 promotes the proliferation, migration and invasion of osteosarcoma through KCNQ1 mediated activation of ERK/MEK signaling pathway.
- DUSP3 restrains the progression and stemness property of osteosarcoma through regulating EGFR/STAT3/SOX2 axis.
- Bayesian-optimized deep learning for identifying essential genes of mitophagy and fostering therapies to combat drug resistance in human cancers.
- HMGCL activates autophagy in osteosarcoma through β-HB mediated inhibition of the PI3K/AKT/mTOR signaling pathway.
- Research progress on cancer-associated fibroblasts in osteosarcoma.
- Constructing a prognostic model for osteosarcoma based on centrosome-related genes and identifying potential therapeutic targets of paclitaxel.
- The homeobox family gene signature predicts the prognosis of osteosarcoma and correlates with immune invasion.
- ZNF692 promotes osteosarcoma cell proliferation, migration, and invasion through TNK2-mediated activation of the MEK/ERK pathway.
- SLC38A5 suppresses ferroptosis through glutamine-mediated activation of the PI3K/AKT/mTOR signaling in osteosarcoma.
- CGREF1 modulates osteosarcoma proliferation by regulating the cell cycle through the Wnt/β-catenin signaling pathway.
- Construction of a prognostic risk score model based on the ARHGAP family to predict the survival of osteosarcoma.
- TRIM26 inhibited osteosarcoma progression through destabilizing RACK1 and thus inactivation of MEK/ERK signaling.
- CircTNPO1 promotes the tumorigenesis of osteosarcoma by sequestering miR-578 to upregulate WNT5A expression.
- Gambogenic acid induces cell death in human osteosarcoma through altering iron metabolism, disturbing the redox balance, and activating the P53 signaling pathway.
- CircUSP48 promotes malignant behavior by regulating CYR61 via miR-365 in osteosarcoma.
- METTL3-mediated m6A modification of circRNF220 modulates miR-330-5p/survivin axis to promote osteosarcoma progression.
- Silencing circUSP48 suppresses osteosarcoma progression by regulating the miR-335/ smad nuclear interacting protein 1 pathway.
- Circadian rhythm-associated lncRNA RP11-414H17.5 as a key therapeutic target in osteosarcoma affects the tumor immune microenvironment and enhances malignancy.
- RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/AKT/mTOR pathway.
- Identification and validation of long noncoding RNA AC083900.1 and RP11-283C24.1 for prediction of progression of osteosarcoma.
- Silencing long non-coding RNA LINC00960 inhibits osteosarcoma proliferation by sponging miR-107 to downregulate SALL4.
- Dissecting the effect of sphingolipid metabolism gene in progression and microenvironment of osteosarcoma to develop a prognostic signature.
- Repurposing Ivermectin to augment chemotherapy's efficacy in osteosarcoma.
- Long non-coding RNA NR2F2-AS1 regulates human osteosarcoma growth and metastasis through miR-425-5p-mediated HMGB2.
- Human umbilical vein endothelial cells derived-exosomes promote osteosarcoma cell stemness by activating Notch signaling pathway.
- MicroRNA-629-5p promotes osteosarcoma proliferation and migration by targeting caveolin 1.
Earlier papers (2016–2020)20
- Proscillaridin A induces apoptosis and inhibits the metastasis of osteosarcoma in vitro and in vivo.
- CDKN2B-AS1 Exerts Oncogenic Role in Osteosarcoma by Promoting Cell Proliferation and Epithelial to Mesenchymal Transition.
- Circ_0010220-mediated miR-503-5p/CDCA4 axis contributes to osteosarcoma progression tumorigenesis.
- Hsa-let-7g promotes osteosarcoma by reducing HOXB1 to activate NF-kB pathway.
- Relationship between red cell distribution width and prognosis of patients with osteosarcoma.
- The Notch Pathway Promotes Osteosarcoma Progression through Activation of Ephrin Reverse Signaling.
- Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
- Synergistic effect of docetaxel combined with cisplatin on inhibiting human osteosarcoma in nude mice.
- LncRNA SNHG12 promotes tumorigenesis and metastasis in osteosarcoma by upregulating Notch2 by sponging miR-195-5p.
- Cinobufagin Induces Apoptosis in Osteosarcoma Cells Via the Mitochondria-Mediated Apoptotic Pathway.
- Peroxiredoxin 1 (PRDX1) Suppresses Progressions and Metastasis of Osteosarcoma and Fibrosarcoma of Bone.
- miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2.
- Cinobufagin induces apoptosis of osteosarcoma cells through inactivation of Notch signaling.
- SOX5 promotes epithelial-mesenchymal transition in osteosarcoma via regulation of Snail.
- LncRNA-ANCR regulates the cell growth of osteosarcoma by interacting with EZH2 and affecting the expression of p21 and p27.
- High CCL5 expression is associated with osteosarcoma metastasis and poor prognosis of patients with osteosarcoma.
- MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma.
- Telomerase reverse transcriptase promotes chemoresistance by suppressing cisplatin-dependent apoptosis in osteosarcoma cells.
- Bispecific antibody suppresses osteosarcoma aggressiveness through regulation of NF-κB signaling pathway.
- Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Wuhan for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Cancer
Neuroblastoma
神经母细胞瘤Led 10 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Wuhan for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led10
- PERK inhibition mitigates acrylamide-induced tau phosphorylation and synaptic deficits via the GSK-3β and ATF4 pathways in human neuroblastoma SH-SY5Y cells.
- L116 Deletion in CSPα Promotes α-Synuclein Aggregation and Neurodegeneration.
- Inhibition of PINK1-Mediated Mitophagy Contributes to Postoperative Cognitive Dysfunction through Activation of Caspase-3/GSDME-Dependent Pyroptosis.
- Neuronal-specific TNFAIP1 ablation attenuates postoperative cognitive dysfunction via targeting SNAP25 for K48-linked ubiquitination.
- Exposure to dithiocarbamate fungicide maneb in vitro and in vivo: Neuronal apoptosis and underlying mechanisms.
- SNAP25 ameliorates postoperative cognitive dysfunction by facilitating PINK1-dependent mitophagy and impeding caspase-3/GSDME-dependent pyroptosis.
- Retinoic Acid Prevents α-Synuclein Preformed Fibrils-Induced Toxicity via Inhibiting STAT1-PARP1 Signaling.
- Exposure to the environmentally toxic pesticide maneb induces Parkinson's disease-like neurotoxicity in mice: A combined proteomic and metabolomic analysis.
- Curcumin Attenuates the PERK-eIF2α Signaling to Relieve Acrylamide-Induced Neurotoxicity in SH‑SY5Y Neuroblastoma Cells.
- Exploration of the molecular characteristics of the tumor-immune interaction and the development of an individualized immune prognostic signature for neuroblastoma.
Other diseases
Myasthenia gravis
重症肌无力Led no English-language PubMed papers on myasthenia gravis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Wuhan for myasthenia gravis93 hospitals in China for myasthenia gravis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06447597
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status4
- A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
- Study of Telitacicept in Generalized Myasthenia Gravis
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Wuhan for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
9 hospitals in Wuhan for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status3
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 3 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Wuhan for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- MicroRNA-23a-3p Is Upregulated in Plasma Exosomes of Bulbar-onset ALS Patients and Targets ERBB4.
- Pain characteristics in amyotrophic lateral sclerosis patients and its impact on quality of life: a prospective observational study in a northern city of China.
- O-GlcNAcylation of TDP-43 suppresses proteinopathies and promotes TDP-43's mRNA splicing activity.
Other diseases
Behçet disease
白塞病Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Wuhan for Behçet disease149 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Alport syndrome
Alport 综合征Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Wuhan for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
IgA nephropathy
IgA 肾病Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Wuhan for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led 2 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 3.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Wuhan for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 2 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 3.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Wuhan for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy
No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Getting in touch
Name card to show staff or a driver
武汉大学人民医院
Renmin Hospital of Wuhan University
武汉
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
RenMin Hospital of WuHan University; Renmin Hospital of WuhanUniversity; PET-CT/MRI Center Renmin Hospital of Wuhan University Wuhan; Qianjiang Hospital Affiliated to Renmin Hospital of Wuhan University; East Hospital of Renmin Hospital of Wuhan University; First Affiliated Hospital of Wuhan University; Hubei General Hospital; Hubei Provincial People's Hospital